Organization · Venture Capital
9vc
9vc is a tech-enabled venture capital firm focused on late-stage drug development and biopharma asset transactions. It operates primarily in Israel, the US, and Europe, leveraging technology to identify and develop underappreciated therapeutic assets.
Overview
What 9vc does
What 9vc is
9vc is a tech-enabled venture capital firm focused on late-stage drug development and biopharma asset transactions. It operates primarily in Israel, the US, and Europe, leveraging technology to identify and develop underappreciated therapeutic assets.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2024
- Approximate age
- About 2 years
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find 9vc elsewhere
Open the official website or a supported primary organization account.
Capability profile
9vc as a funder
Investment thesis
9vc focuses on asset arbitrage in late-stage drug development, leveraging technology and expertise to identify undervalued therapeutic assets and facilitate their development into viable companies or partnerships.
Focus narrative
9vc specializes in investing in late-stage clinical development companies, particularly those involved in drug development. The organization emphasizes asset arbitrage, seeking to capture value in opportunities that may be overlooked by others. By combining technology with deep industry expertise, 9vc aims to reduce risk and accelerate the realization of value in the biopharma sector.
Value beyond capital
9vc adds value to its portfolio companies by leveraging its proprietary technology and extensive network in the biopharma industry. The organization focuses on identifying underappreciated drug programs and facilitating their development through strategic partnerships, thereby accelerating the path to market and enhancing investor returns.
Focus and fit
- Stages
- Series C · Series D · Growth Equity
- Sectors
- Biotech & Life Sciences
- Regions
- United StatesEurope
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 1
Portfolio context
Leona Bio (NASDAQ: LONA): A clinical-stage biopharma company formerly known as Athira Pharma, Leona Bio is focused on developing a phase 2 ready pipeline, including a mid-phase 3 asset for treating ESR1-mutant metastatic breast cancer and a novel small molecule for neurodegenerative diseases.
Common questions
What to know about 9vc
Upseed classifies 9vc under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.